Failed Pediatric Study Data To Get FDA Review At Patient Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency officials plan discussion of how analysis of failed pediatric clinical trial data can improve future trials during annual patient network meeting.
You may also be interested in...
J&J’s Clinical Data Disclosure Strategy Focuses On Collaboration With Yale University Group
In what appears to be the most expansive policy to date on release of clinical trial data, J&J will use an existing outside group and will share full clinical study reports and patient-level data regardless of when the studies were conducted.
“Patient Voice” Report Puts Chronic Fatigue Symptoms, Treatments In Benefit/Risk Framework
FDA report on CFS/myalgic encephalomyelitis is first of its kind from the patient-focused drug development initiative under PDUFA V. Incorporating comments from hundreds of patients and caregivers into a structured framework shows how the input may support a benefit/risk assessment for new products.
FDA To Be More Vigilant About Proposed Clinical Trial Exclusions
FDA’s Bob Temple says “document” being drafted will instruct reviewers to pay more attention during sponsor meetings and eliminate unnecessary exclusions from protocols.